Mast, University of Pittsburgh deal

Mast's Aires Pharmaceuticals Inc. subsidiary and the university partnered to conduct an open-label, dose-escalation, U.S. Phase I/II trial to evaluate the biotech's AIR001 to treat Pseudomonas aerugin...